Walker's comment in the MASS Medical interview = 21% ABPatients high endotoxin and no bacteria present showed a 21% absolute benefit, or a 50% realtive benefit. Walker described this population in his MASS Medical interview, and now we have the data to back it up.
We also confirmed what the Cormark analyst and the FDA told us at the interim analysis point and are saving 11% of those that are not "too far gone" ( see the per protocol patient population )
This will see a SP WELL beyond the $2 teaser we saw last Fall
CONGRATS to LONGS and Congrats to Walker et al for their scientific success!